A Phase 3 Study of Ranolazine in Subjects With Type 2 Diabetes Who Are Inadequately Controlled on Metformin Alone

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 442 participants.

Also called NCT01555164

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 442 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01555164
  • EudraCT 2012-001259-37
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada, Czechia, Hungary, India, Israel, Mexico, Poland, Russia, South Africa, Ukraine (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01555164. Randomized; double masking; primary purpose treatment. Start 2012-06 (registry gives no type); primary completion 2013-09 (actual). Results posted on 2014-09-23.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Phase 3 Study of Ranolazine in Subjects With Type 2 Diabetes Who Are Inadequately Controlled on Metformin Alone
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Ranolazine
Intervention (Drug)
Placebo to match ranolazine
Intervention (Drug)
Metformin
Intervention (Drug)
Placebo to match metformin
Intervention (Behavioral)
Diet
Intervention (Behavioral)
Exercise
Lead sponsor
Gilead Sciences (class: industry)

Record details

Record id
cardio:ct-nct01555164
Content hash
1ab49d023262cce53f8787e812a28983870cdd3c1162afd656bb5746b04465ca